Departments of Anesthesiology, Pain Medicine and Perioperative Care, Psychiatry and Pharmacology Dalhousie University, Halifax, Nova Scotia, Canada,
J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301. doi: 10.1007/s11481-015-9600-6. Epub 2015 Mar 22.
An updated systematic review of randomized controlled trials examining cannabinoids in the treatment of chronic non-cancer pain was conducted according to PRISMA guidelines for systematic reviews reporting on health care outcomes. Eleven trials published since our last review met inclusion criteria. The quality of the trials was excellent. Seven of the trials demonstrated a significant analgesic effect. Several trials also demonstrated improvement in secondary outcomes (e.g., sleep, muscle stiffness and spasticity). Adverse effects most frequently reported such as fatigue and dizziness were mild to moderate in severity and generally well tolerated. This review adds further support that currently available cannabinoids are safe, modestly effective analgesics that provide a reasonable therapeutic option in the management of chronic non-cancer pain.
根据 PRISMA 系统评价报告卫生保健结果指南，对评估大麻素治疗慢性非癌性疼痛的随机对照试验进行了更新的系统评价。自上次评价以来，有 11 项试验符合纳入标准。这些试验的质量非常好。其中 7 项试验显示出显著的镇痛效果。一些试验还显示出次要结局（如睡眠、肌肉僵硬和痉挛）的改善。最常报告的不良反应，如疲劳和头晕，其严重程度为轻度至中度，且通常可耐受。本综述进一步支持了目前可用的大麻素是安全的、适度有效的镇痛药，为慢性非癌性疼痛的治疗提供了合理的治疗选择。
